在一线 - 突变型晚期非小细胞肺癌中，阿米万他单抗联合拉泽替尼与奥希替尼的对比研究
Amivantamab plus lazertinib vs. osimertinib in first-line -mutant advanced non-small cell lung cancer.
作者信息
Hasan Nazmul, Nagasaka Misako
机构信息
University of California Irvine School of Medicine, Orange, CA, USA.
出版信息
Expert Rev Respir Med. 2025 Feb 20:1-10. doi: 10.1080/17476348.2025.2467338.
INTRODUCTION
The first-line treatment landscape for patients with NSCLC harboring sensitizing mutations is rapidly evolving. Initially, osimertinib was the one and only option over earlier generation EGFR inhibitors based on the positive PFS and OS results from the FLAURA study.
AREAS COVERED
This paper reviews and compares the pivotal studies that led to the approval of combination treatment with a focus on the efficacy and safety of amivantamab plus lazertinib in the front-line setting. The literature reviewed in this paper primarily includes key studies published in well-established journals and oncological conferences, such as ASCO, ESMO, and NEJM, between 2018 and 2024.
EXPERT OPINION
Recent advancements, including the results of FLAURA-2 and MARIPOSA, have introduced combination therapies that demonstrate enhanced efficacy.
引言
对于携带敏感突变的非小细胞肺癌（NSCLC）患者，一线治疗格局正在迅速演变。最初，基于FLAURA研究中积极的无进展生存期（PFS）和总生存期（OS）结果，奥希替尼是优于早期一代表皮生长因子受体（EGFR）抑制剂的唯一选择。
涵盖领域
本文回顾并比较了促成联合治疗获批的关键研究，重点关注阿美替尼单抗联合拉泽替尼一线治疗的疗效和安全性。本文所回顾的文献主要包括2018年至2024年间发表于知名期刊和肿瘤学会议（如美国临床肿瘤学会（ASCO）、欧洲肿瘤内科学会（ESMO）和《新英格兰医学杂志》（NEJM））上的关键研究。
专家观点
包括FLAURA-2和MARIPOSA研究结果在内的近期进展引入了疗效更佳的联合疗法。
Zotero 插件